# 6 vs 3 Cycles of Neoadjuvant Chemotherapy for Potentially Resectable Locally Advanced Thymic Epithelial Tumors

> **NCT07463313** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine** · enrollment: 116 (estimated)

## Conditions studied

- Thymoma and Thymic Carcinoma

## Interventions

- **DRUG:** Cyclophosphamide, Doxorubicin, and Cisplatin (CAP)
- **DRUG:** nab-Paclitaxel and Carboplatin

## Key facts

- **NCT ID:** NCT07463313
- **Lead sponsor:** Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03
- **Primary completion:** 2029-03
- **Final completion:** 2032-03
- **Target enrollment:** 116 (ESTIMATED)
- **Last updated:** 2026-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07463313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07463313, "6 vs 3 Cycles of Neoadjuvant Chemotherapy for Potentially Resectable Locally Advanced Thymic Epithelial Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07463313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*